Under the leadership of Prof. Mohanasankar Sivaprasad, the TARaNGaM hub at IIT Madras is developing next-generation diagnostics for currently unmet clinical needs. This initiative forms a critical part of a broader national strategy by the Indian Council of Medical Research to revolutionize the domestic healthcare landscape. By establishing seven specialized hubs at the country’s most prestigious academic institutions, the organization is fostering an environment where indigenous, affordable, and high-quality medical devices can flourish. The selected institutions, including the Indian Institutes of Technology in Bombay, Delhi, Kanpur, Kharagpur, and Madras, along with the Indian Institute of Science in Bengaluru and Amrita Vishwa Vidyapeetham, represent the pinnacle of scientific research in India. This move is designed to address significant gaps in the healthcare system, specifically focusing on primary care, chronic disease management, and surgical materials that are often imported.
Specialized Mandates: Strategic Innovation and Methodology
To ensure comprehensive coverage of the diverse medical needs across the subcontinent, the council has assigned specific technological domains to each participating institution based on their core strengths. For instance, IIT Bombay is currently working to create portable screening tools and point-of-care diagnostics for resource-limited settings. Simultaneously, Amrita Vishwa Vidyapeetham is directing its expertise toward the specialized fields of ophthalmology and vascular health. Other centers, such as the Indian Institute of Science in Bengaluru and IIT Kharagpur, are merging materials science with digital health to develop advanced biomaterials and frugal diagnostics. At IIT Delhi, the CAR-PATH center is dedicated to translating research into priority technologies, while IIT Kanpur has committed to delivering ten specific healthcare products. This targeted division of labor ensures that every aspect of the medical spectrum receives dedicated attention, fostering a cohesive ecosystem of innovation across the nation.
A defining feature of this national initiative is the shift toward an evidence-based approach for identifying technological requirements. Rather than allowing academic interest alone to dictate the research agenda, the council conducted extensive consultations with clinicians practicing in various environments. This included feedback from specialists in metropolitan tier-1 hospitals as well as general practitioners in smaller tier-2 and tier-3 city clinics. This collaborative feedback loop resulted in a curated list of approximately 100 priority medical technologies that the Indian healthcare system currently lacks or imports at unsustainable costs. Each hub is required to select at least eight to ten technologies from this list, maintaining a balanced portfolio that includes both low-risk diagnostic tools and high-risk, life-saving medical devices. This structured approach ensures that the resulting innovations are not only scientifically advanced but also practically relevant and market-ready.
Financial Sustainability: Commercialization and Implementation
To facilitate these ambitious goals, the central council is providing substantial financial backing, offering up to ₹15 crore to each center over a five-year period starting from 2026. This funding is specifically directed toward building the necessary infrastructure for prototyping, testing, and technology transfer. However, the vision for these hubs extends far beyond this initial financial window. A core requirement of the program is that these centers must eventually become self-sustaining entities. The host institutions are expected to integrate these research activities into their permanent academic frameworks, ensuring that technology development continues long after the grants are used. Furthermore, the program is invested in human capital, aiming to train a new generation of engineers and scientists who understand the complex regulatory and clinical requirements of manufacturing. This ensures a steady pipeline of expertise to support the growing medical technology ecosystem.
The ultimate measure of success for this initiative involved the transition from the laboratory to the bedside through rigorous commercialization efforts. Stakeholders prioritized regulatory compliance and international standards during the early research stages, which successfully streamlined the path to market for these indigenous products. By reducing the country’s reliance on expensive imported medical equipment, the program effectively lowered healthcare costs for the general population. The road forward was secured by establishing reliable supply chains and conducting rigorous clinical trials through strategic partnerships with industrial manufacturers. This unified roadmap provided a clear trajectory for the nation to evolve from a consumer of global medical technology into a self-reliant producer. Consequently, the council’s investment in domestic research established a sustainable ecosystem that served as a blueprint for other developing nations to follow.
